US states told to be prepared for vaccine distribution by November 1


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ US states told to be prepared for vaccine distribution by November 1
Though it's not clear if the vaccine would be ready by delivery

The director of the Centers for Disease Control and Prevention told governors last week to prepare for the "large-scale" distribution of a coronavirus vaccine by Nov. 1, according to a letter obtained Wednesday by NBC News.

In the Aug. 27 letter, the director, Dr. Robert Redfield, said the CDC had contracted with a pharmaceutical company, McKesson Corp., to potentially distribute hundreds of millions of vaccine doses to health departments and medical facilities across the country in the fall.

Redfield called the effort "massive" and asked governors for their help expediting applications for distribution facilities that will be set up and operated by McKesson.

"If necessary," Redfield added, the agency "asks you to consider waiving requirements that would prevent these facilities from being fully operational by November 1, 2020."

It remains highly uncertain, however, whether a vaccine will be ready by then or which manufacturer will make it. The Nov. 1 target date is two days before the presidential election.

A planning document obtained by The New York Times described the "vaccine landscape" as "evolving and uncertain," but it described different hypothetical supply and operations scenarios for local officials and doctors. One scenario showed 2 million doses distributed by the end of October, and another showed 10 million to 20 million doses by the end of November.

Full coverage of the coronavirus outbreak

In a statement, Banner Health, which operates 28 hospitals in Arizona, said it had been asked by the agency and local health officials to "proactively prepare" for vaccine distribution.

"While we do not yet know definitively when a vaccine will be available, pre-planning will ensure we can effectively meet the needs of our communities," the company said.

Food and Drug Administration Commissioner Stephen Hahn told The Financial Times that the FDA could fast-track a vaccine, giving a developer federal approval before rigorous Phase 3 clinical trials are completed.

"We may find that appropriate," he told the newspaper in a story published Sunday. "We may find that inappropriate. We will make a determination."

It wasn't clear what developer may get the approval. One company working on a vaccine, AstraZeneca, announced Monday that it was beginning Phase 3 trials this week.Two other vaccine candidates — one created by the National Institutes of Health and manufactured by Moderna Inc. and another developed by Pfizer Inc. and Germany's BioNTech — began trials this summer.

Earlier Wednesday, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on NBC's "TODAY" that he believed a vaccine would be developed by the end of the year. But Fauci added that he wouldn't be comfortable with a vaccine unless it was shown in clinical trials "to be clearly safe and effective."

He added that he had observed many trials that operated under emergency use authorizations, the FDA's method of fast-tracking medical products. "But they've been done when there was enough data that you would really feel comfortable that it was safe," he said.

Story Credit - https://www.nbcnews.com 

Tags : #CDC #VaccineDistribution #USStates #NewYorkTimes #NBCNews #AnthonyFauci #LatestCovidNewsSep3

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Why Modern Lifestyle Causes Chronic InflammationAugust 05, 2026
Endometriosis Awareness: Understanding the Silent Condition Affecting Millions of Indian WomenAugust 05, 2026
A Complete Guide to Pregnancy Health Tips for Indian Women: Nutrition, Wellness, and What Every Expectant Mother Should KnowAugust 05, 2026
Why Preventive Healthcare for Children Is One of the Most Important Investments India Can MakeAugust 04, 2026
The Role of Pathology in Healthcare: From Diagnosis to Disease PreventionAugust 04, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 04, 2026
Comprehensive Evaluation of Syncope: Cardiac vs. Neurological Origin WorkupsAugust 04, 2026
Common Medical Terms Explained: A Plain-Language Guide for Indian Patients and Healthcare SeekersAugust 03, 2026
Why Radiology Is the Backbone of Modern Medical Diagnosis and TreatmentAugust 03, 2026
Managing Urban Stress: Science-Backed Strategies for Mental Resilience in 2026 August 01, 2026
Managing Chronic Inflammation: The Role of Anti-Inflammatory Indian SuperfoodsAugust 01, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 01, 2026
Early Markers of Glaucoma: Structural vs. Functional Ophthalmic Diagnostic ProtocolsAugust 01, 2026
Managing Complex Diabetic Foot Ulcers: Multidisciplinary Wound Care, Offloading, and RevascularizationAugust 01, 2026
The Future of Preventive Medicine: How India Is Moving From Cure to PreventionAugust 01, 2026
Why Young Indians Are Facing Heart Problems: Causes, Symptoms, and PreventionAugust 01, 2026
The Future of Preventive Screening: AI-Driven Early Cancer Detection in IndiaJuly 31, 2026
The Impact of Climate Change on Allergic Respiratory Diseases in Indian Cities July 31, 2026
Electronic Medical Records: What They Are, Why They Matter, and How India Is Embracing ThemJuly 31, 2026
Heatwave Health Risks in India: Symptoms, Treatment, and Prevention StrategiesJuly 31, 2026